Nos publications

Vous retrouverez ici l'ensemble des publications mentionnant le réseau NS-PARK/FCRIN et les liens pour y accéder. Bonne lecture !

  • Desjardins C, Mongin M, de Liège A, Degos B. Correction to: Hypocortisolism as an unusual but treatable cause of dystonia‑parkinsonism. J Neurol. 2023 Mar 13.
  • Angelov T, Chamova T, Atemin S, Tet al. Novel variant c.92T > G (p.Val31Gly) in the PFN1 gene (ALS18) responsible for a specific phenotype in a large Bulgarian amyotrophic lateral sclerosis pedigree. Front Neurol. 2023 Feb 9;14:1094234.
  • Lees A, Tolosa E, Stocchi F, et al. Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach. Expert Rev Neurother. 2023 Jan;23(1):15-24. 
  • Fabbri M, Barbosa R, Rascol O. Correction to: Off-time Treatment Options for Parkinson's Disease. Neurol Ther. 2023 Feb 2.
  • Mounir Alaoui O, Charbonneau PF, Prin P, et al. TMEM151A as an alternative to PRRT2 in paroxysmal kinesigenic dyskinesia: About three new cases. Parkinsonism Relat Disord. 2023 Mar;108:105295.
  • Fabbri M, Barbosa R, Rascol O. Off-time Treatment Options for Parkinson's Disease. Neurol Ther. 2023 Jan 12. 

 

  • Desjardins C, Mongin M, de Liège A, Degos B. Hypocortisolism as an unusual but treatable cause of dystonia-parkinsonism. J Neurol. 2022 Dec 10.
  • Pongmala C, Fabbri M, Zibetti M, et al. Gait and axial postural abnormalities correlations in Parkinson's disease: A multicenter quantitative study. Parkinsonism Relat Disord. 2022 Dec;105:19-23.
  • Mangone G, Houot M, Gaurav R, et al. Relationship between Substantia Nigra Neuromelanin Imaging and Dual Alpha-Synuclein Labeling of Labial Minor in Salivary Glands in Isolated Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. Genes (Basel). 2022 Sep 24;13(10):1715. 
  • Khedher L, Bonny JM, Marques A, et al; R study group. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease. Neuroimage Clin. 2022;36:103231. Cette publication porte sur l'étude MPI-R2*. 
  • Chendo I, Fabbri M, Godinho C, et al. High frequency of Depressive Disorders and Suicidal Phenomena in Late-Stage Parkinson´s Disease - A Cross-Sectional Study. J Geriatr Psychiatry Neurol. 2022 Oct 22:8919887221135556.
  • Degos B, Pouget P, Missal M. From anticipation to impulsivity in Parkinson's disease. NPJ Parkinsons Dis. 2022 Oct 3;8(1):125.
  • Devos D, Labreuche J, Rascol O, et al; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson's Disease. N Engl J Med. 2022 Dec 1;387(22):2045-2055.  Cette publication porte sur l'étude FAIR-PARK-II. 
  • Rocha JF, Ebersbach G, Lees A, et al. The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II. Front Neurol. 2022 Aug 23;13:994114.
  • Krismer F, Palma JA, Calandra-Buonaura G, et al. The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations. Mov Disord. 2022 Sep 8. 
  • Boussac M, Arbus C, Colin O, et al; PREDISTIM study group. Personality assessment with Temperament and Character Inventory in Parkinson's disease. Parkinsonism Relat Disord. 2022 Aug 19;103:34-41. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Vignoud G, Desjardins C, Salardaine Q, et al. Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson's Disease. J Parkinsons Dis. 2022 Aug 10.
  • Lang AE, Siderowf AD, Macklin EA, et al; SPARK Investigators. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. Cette publication porte sur l'étude SPARK. 
  • Chelban V, Nikram E, Perez-Soriano A, et al. methoidNeurofilament light levels predict clinical progression and death in multiple system atrophy. Brain. 2022 Jul 29;awac253.
  • Betrouni N, Moreau C, Rolland AS, et al; PREDISTIM Study Group. Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test? J Parkinsons Dis. 2022 Jul 18. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Lapostolle A, Houot M, Mongin M, Degos B. Comparison of Botulinum neurotoxin efficiency in dystonia associated with Parkinson's disease and atypical parkinsonism: a retrospective study with a self-reported improvement scale.J Neurol. 2022 Jul 19. 
  • van Munster M, Stümpel J, Thieken F, et al; iCARE-PD consortium. The Role of Parkinson Nurses for Personalizing Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis. 2022;12(6):1807-1831. 
  • Ferreira JJ, Poewe W, Rascol O, et al. Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. Neurol Ther. 2022 Sep;11(3):1409-1425.
  • Prange S, Klinger H, Laurencin C, Danaila T, Thobois S. Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment. Drugs Aging. 2022 Jun;39(6):417-439. 
  • Prange S, Lin Z, Nourredine M, et al; Predistim study group. Limbic Stimulation Drives Mania in STN-DBS in Parkinson Disease: A Prospective Study. Ann Neurol. 2022 Sep;92(3):411-417. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Fabbri M, Coelho M, Garon M, et al, On Behalf Of iCARE-Pd Consortium. Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. J Pers Med. 2022 May 18;12(5):813.
  • Devignes Q, Daoudi S, Viard R, et al; PREDISTIM working group. Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications. J Parkinsons Dis. 2022;12(5):1507-1526. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Pongmala C, Artusi CA, Zibetti M, et al. Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study. Parkinsonism Relat Disord. 2022 Apr;97:91-98.
  • Saulnier T, Philipps V, Meissner WG, et al. Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout. Methods. 2022 Jul;203:142-151. 
  • Chaudhuri KR, Odin P, Ferreira JJ, et al. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial. BMC Neurol. 2022 Mar 12;22(1):88.
  • Severiano E Sousa C, Fabbri M, Godinho C, et al. Profile of cognitive impairment in late-stage Parkinson's disease. Brain Behav. 2022 Apr;12(4):e2537. 
  • Béreau M, Castrioto A, Lhommée E, et al. Fatigue in de novo Parkinson's Disease: Expanding the Neuropsychiatric Triad? J Parkinsons Dis. 2022;12(4):1329-1337. 
  • Prange S, Metereau E, Maillet A, et al. Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease. Mov Disord. 2022 Jun;37(6):1211-1221. 
  • Rascol O, Tönges L, deVries T, et al; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022 Mar;96:65-73. Cette publication porte sur les études ALLAY-LID-I et ALLAY-LID-II. 
  • Rascol O, Medori R, Baayen C, et al; AMBLED Study Group. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Mov Disord. 2022 May;37(5):1088-1093. Cette publication porte sur l'étude AMBLED. 
  • Fabbri M, Ferreira JJ, Rascol O. COMT Inhibitors in the Management of Parkinson's Disease. CNS Drugs. 2022 Mar;36(3):261-282. 
  • Ganapathy S R, Levová K, Kotačková L, et al. Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder. Mov Disord. 2022 May;37(5):983-992.
  • Tödt I, Al-Fatly B, Granert O, et al. The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life. Mov Disord. 2022 Feb;37(2):291-301.
  • Boussac M, Arbus C, Klinger H, et al; PREDISTIM study group. Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson's Disease (PSYCHO-STIM II). J Parkinsons Dis. 2022;12(2):699-711. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Montanaro E, Romagnolo A, Fabbri M, et al. Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson's disease. J Neurol. 2022 Mar;269(3):1538-1545.
  • Chendo I, Fabbri M, Godinho C, Moiron Simões R, Severiano Sousa C, Coelho M, Voon V, Ferreira JJ. High frequency of psychosis in late-stage Parkinsońs disease. Clin Park Relat Disord. 2021 Nov 24;5:100119.
  • Foubert-Samier A, Pavy-Le Traon A, Saulnier T, et al. An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale. Parkinsonism Relat Disord. 2021 Nov 30;94:40-44. 
  • Rocha JF, Ebersbach G, Lees A, et al. The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. Front Neurol. 2021 Nov 5;12:754016.
  • Boussac M, Arbus C, Dupouy J, et al; PREDI-STIM study group. Personality dimensions of patients can change during the course of parkinson's disease. PLoS One. 2021 Jan 7;16(1):e0245142. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Artusi CA, Sarro L, Imbalzano G, et al. Safety and efficacy of tolcapone in Parkinson's disease: systematic review. Eur J Clin Pharmacol. 2021 Jun;77(6):817-829. 
  • Boucherie DM, Duarte GS, Machado T, et al. Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. J Parkinsons Dis. 2021;11(2):421-429.
  • Katzenschlager R, Poewe W, Rascol O, et al. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021 Feb;83:79-85. Cette publication porte sur les résultats de l'étude TOLEDO. 
  • Frisaldi E, Bottino P, Fabbri M, et al. Effectiveness of a dance-physiotherapy combined intervention in Parkinson's disease: a randomized controlled pilot trial. Neurol Sci. 2021 Mar 20.
  • Leung C, Rascol O, Fabbri M. Opicapone for Parkinson's disease: clinical evidence and future perspectives. Neurodegener Dis Manag. 2021 Jun;11(3):193-206. 
  • Rascol O, Cochen de Cock V, Pavy-Le Traon A, et al; MSA-FLUO Study Group. Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. Mov Disord. 2021 Jul;36(7):1704-1711. Cette publication porte sur les résultats de l'étude MSA-FLUO. 
  • Tolosa E, Ebersbach G, Ferreira JJ, et al. The Parkinson's Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson's Disease in Patients and their Carers. J Parkinsons Dis. 2021;11(3):1309-1323. 
  • Poewe W, Volc D, Seppi K, et al; AFF011 investigators. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. J Parkinsons Dis. 2021;11(3):1079-1089. Cette publication porte sur les résultats de l'étude SYMPATH.
  • Severiano E Sousa C, Fabbri M, Godinho C, et al. Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease. Front Neurol. 2021 May 20;12:652424.
  • Fernández-Rodríguez B, Dupouy J, Harroch E, et al. Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation. Rev Neurol (Paris). 2021 Oct;177(8):919-923.
  • van Munster M, Stümpel J, Thieken F, et al. Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. J Pers Med. 2021 Jun 30;11(7):623. 
  • Olanow CW, Poewe W, Rascol O, Stocchi F. On-Demand Therapy for OFF Episodes in Parkinson's Disease. Mov Disord. 2021 Oct;36(10):2244-2253.
  • Witzel S, Frauhammer F, Steinacker P, et al. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl Neurodegener. 2021 Aug 26;10(1):31.
  • Hauser RA, Hattori N, Fernandez H, et al. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663-1675.
  • Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. Expert Rev Neurother. 2021 Sep;21(9):1019-1033.
  • Faggianelli F Jr, Loundou A, Baumstarck K, et al; NS-Park FCRIN Network. Validation of a non-motor fluctuations questionnaire in Parkinson's disease. Rev Neurol (Paris). 2021 Sep 24:S0035-3787(21)00671-8.
  • Besse-Pinot E, Pereira B, Durif F, Fantini ML, Durand E, Debilly B, Derost P, Moreau C, Hainque E, Rouaud T, Eusebio A, Benatru I, Drapier S, Guehl D, Rascol O, Maltête D, Lagha-Boukbiza O, Giordana C, Tir M, Thobois S, Hopes L, Hubsch C, Jarraya B, Rolland AS, Corvol JC, Devos D, Marques A; Predistim study group. Preoperative REM Sleep Behavior Disorder and Subthalamic Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery. Neurology. 2021 Nov 16;97(20):e1994-e2006. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson's disease and other movement disorders. Lancet Neurol. 2021 Oct 19:S1474-4422(21)00249-0.
  • Corvol JC, Azulay JP, Bosse B, et al; THN102-202 Study Investigators. THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. Mov Disord. 2021 Oct 28. Cette publication porte sur les résultats de l'étude THN102-202.
  • Marques A, Brefel-Courbon C. Chronic pain in Parkinson's disease: Clinical and pathophysiological aspects. Rev Neurol (Paris). 2021 Apr;177(4):394-399.
  • Santin MDN, Voulleminot P, Vrillon A, et al; Predistim Study Group. Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study. Mov Disord. 2021 Mar;36(3):750-757. Cette publication porte sur les résultats d'une étude ancillaire de PREDISTIM.
  • Morgante F, Oppo V, Fabbri M, et al.  Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age. J Neurol. 2021 May;268(5):1728-1737.
  • Rascol O, Negre-Pages L, Damier P, et al; COPARK Study Group. Correction to: Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. J Neural Transm (Vienna). 2021 Jun;128(6):871-872. Erratum for: J Neural Transm (Vienna). 2020 Dec;127(12):1607-1617.
  • LeWitt PA, Aradi SD, Hauser RA, Rascol O. The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S54-S63. 
  • Lastennet D, Mariani LL, Rascol O, et al. Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists. CNS Drugs. 2020 Dec;34(12):1267-1274. Cette publication porte sur les résultats de l'étude DUMP. 
  • Simões RM, Castro Caldas A, Grilo J, et al. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. BMC Neurol. 2020 Nov 27;20(1):432.
  • Markaki I, Bergström S, Tsitsi P, et al. Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease. Mov Disord. 2020 Nov;35(11):2101-2106. 
  • Fabbri M, Zibetti M, Calandra-Buonaura G, et al. Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia. Mov Disord Clin Pract. 2020 Sep 18;7(8):930-939.
  • Sharpe G, Macerollo A, Fabbri M, Tripoliti E. Non-pharmacological Treatment Challenges in Early Parkinson's Disease for Axial and Cognitive Symptoms: A Mini Review. Front Neurol. 2020 Sep 25;11:576569.
  • Grimes D, Antonini A, Ferreira JJ, et al. Patient-centred management of Parkinson's disease. Lancet Neurol. 2020 Nov;19(11):887-888.
  • Meissner WG, Traon AP, Foubert-Samier A, et al; AFF009 Study Investigators. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov Disord. 2020 Nov;35(11):1957-1965. Cette publication porte sur les résultats de l'étude SYMPATH.
  • Rascol O, Negre-Pages L, Damier P, et al; COPARK Study Group. Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. J Neural Transm (Vienna). 2020 Dec;127(12):1607-1617. 
  • Fabbri M, Caldas AC, Ramos JB, et al. Moving towards home-based community-centred integrated care in Parkinson's disease. Parkinsonism Relat Disord. 2020 Sep;78:21-26.
  • Fabbri M, Kauppila LA, Ferreira JJ, Rascol O. Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. J Parkinsons Dis. 2020;10(s1):S75-S83. 
  • de Germay S, Conte C, Rascol O, Montastruc JL, Lapeyre-Mestre M. β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study. CNS Drugs. 2020 Jul;34(7):763-772.
  • Fabbri M, Zibetti M, Rizzone MG, et al. Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease? Mov Disord. 2020 Jul;34(7):763-772.
  • Granon B, Bénard V, Devos D, Geoffroy PA, Vaiva G, Amad A. Efficacy of tDCS for bipolar depression in a patient with spinocerebellar ataxia: A case report. Bipolar Disord. 2020 Jun;22(4):422-424. 
  • Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC; DIGPD study group Steering committee, . Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism Relat Disord. 2020 May 1;75:30-33. Cette publication porte sur les résultats de l'étude DIG-PD.
  • Phillipps C, Longato N, Béreau M, et al. Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study. Mov Disord. 2020 Jun;35(6):1080-1081. Cette publication porte sur les résultats de l'étude BADGE-PD.
  • Rascol O, Negre-Pages L, Damier P, et al; COPARK Study Group.  Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. Drugs Aging. 2020 Mar;37(3):215-223.
  • Blin O, Lefebvre MN, Rascol O, Micallef J. Orphan drug clinical development. Therapie. 2020 Apr;75(2):141-147. 
  • Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020 Feb;16(2):97-107.
  • Devos D, Cabantchik ZI, Moreau C, et al; FAIRPARK-II and FAIRALS-II studygroups. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 2020 Feb;127(2):189-203. Cette publication est relative au concept de l'étude FAIRPARK-II.
  • Leal Rato M, Rascol O, Ferreira JJ. The "long and winding road" of the disease-modifying effects of levodopa has not ended yet. Mov Disord. 2020 Mar;35(3):397-399. 
  • Grosset DG, Dhall R, Gurevich T, et al. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 Feb;71:4-10. Cette publication porte sur les résultats de l'étude CVT-301.
  • Meissner WG, Fernagut PO, Dehay B, et al. Multiple System Atrophy: Recent Developments and Future Perspectives. Mov Disord. 2019 Nov;34(11):1629-1642.
  • Lee PC, Artaud F, Cormier-Dequaire F, et al; DIGPD Study Group. Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. Mov Disord. 2019 Nov;34(11):1663-1671. Cette publication porte sur les résultats de l'étude DIG-PD. 
  • Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C. How to diagnose parkinsonian central pain? Parkinsonism Relat Disord. 2019 Jul;64:50-53.
  • Mariani LL, Doulazmi M, Chaigneau V, et al; NS-Park/F-CRIN Network study group. Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort? Parkinsonism Relat Disord. 2019 Jul;64:226-234. Cette publication porte sur les données de la cohorte NS-PARK.
  • Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long- term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019 Jul;26(7):953-960.
  • Marques A, Vidal T, Pereira B, Bet al; DIGPD study group. French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). Parkinsonism Relat Disord. 2019 Jun;63:117-123. Cette publication porte sur les résultats d'une étude ancillaire de DIG-PD. 
  • Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. Expert Opin Pharmacother. 2019 Apr;20(6):635-645. 
  • Vergnet S, Hives F, Foubert-Samier A, et al. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism Relat Disord. 2019 Jun;63:199-203. 
  • Rascol O. CVT-301 for Parkinson's disease: dose and effect size issues. Lancet Neurol. 2019 Feb;18(2):128-130.
  • Nemmi F, Pavy-Le Traon A, Phillips OR, et al. A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson's disease, multiple system atrophy and healthy control. Neuroimage Clin. 2019;23:101858.
  • Prange S, Danaila T, Laurencin C, Caire C, Metereau E, Merle H, Broussolle E, Maucort-Boulch D, Thobois S. Age and time course of long-term motor and nonmotor complications in Parkinson’s disease. Neurology. 2019 Jan 8;92(2):e148-e160.
     
  • Charvin D, Medori R, Hauser R, Rascol O. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov 2018 Nov;17(11):804-822.
  • Corvol JC, Durif F, Meissner WG, et al; French NS-Park/F-CRIN Network. Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial. Parkinsonism Relat Disord. 2018 Oct 4. pii: S1353-8020(18)30431-0. Cette publication porte sur les résultats de l'étude CT-CVXL-0107-01.
  • Corvol JC, Artaud F, Cormier-Dequaire F, et al; DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018 Jul 17;91(3):e189-e201. 
  • Moreau C, Duce JA, Rascol O, et al; FAIRPARK-II study group. Iron as a therapeutic target for Parkinson's disease. Mov Disord. 2018 Apr;33(4):568-574. Cette publication porte sur le rationnel scientifique de l'étude FAIRPARK-II. 
  • Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP, Payoux P, Meissner WG, Rascol O. MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Mov Disord. 2018 Apr;33(4):600-608.
  • Cormier-Dequaire F, Bekadar S, Anheim M, Let al; BADGE-PD study group. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Mov Disord. 2018 Dec;33(12):1878-1886. Cette publication porte sur les résultats de l'étude BADGE-PD. 
  • Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, Rascol O. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. Mov Disord. 2018 Oct;33(10):1528-1539. 
  • Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo- controlled trial. Lancet Neurol. 2018 Sep;17(9):749-759. Cette publication porte sur les résultats de l'étude TOLEDO. 
  • You H, Mariani LL, Mangone G, Le Febvre de Nailly D, Charbonnier-Beaupel F, Corvol JC. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res. 2018 Jul;373(1):111-135.
  • Dufournet B, Nguyen K, Charles P, et al. Parkinson's disease associated with 22q11.2 deletion: Clinical characteristics and response to treatment. Rev Neurol (Paris). 2017 Jun;173(6):406-410.
  • Laloux C, Gouel F, Lachaud C, et al. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease? Neurobiol Dis. 2017 Jul;103:24-31. 
  • Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. Expert Rev Neurother. 2017 Jul;17(7):649-659. 
  • Perez-Lloret S, Negre-Pages L, Damier P, et al; of the COPARK Study Group. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 2017 Dec ;24(12):1532-1538. 
  • Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017 Jun 6;88(23):2198-2206. 
  • Thibault L, Rascol O, Corvol JC, et al. New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. Mov Disord. 2017 Oct;32(10):1365-1370. 

Partager

Mis à jour le 30 mai 2023